by Kerstin Hein, Simon Fradin, Helmut Kewes, Martina Graßl, and Nicole Faust
Volume 15, Issue 4 (Winter 2016/2017)
A rapid increase in the number of gene therapy trials and products has led to a comparable increase in the need for industrial production of viral gene therapy vectors such as lentiviral, adeno-associated, and adenoviral vectors. Current production systems are limited with respect to scalability and robustness. With our CAP® and CAP-T™ cell lines, we have developed a novel system for high-density suspension culture, efficient and reproducible transfection, and highly efficient production of viral vectors. By upstream process optimization, we have obtained a robust and high-density fed-batch culture system which can be scaled in any current bioreactor format. A design-of-experiments approach has been employed to optimize transient production of lentiviral vectors with significantly higher titers than can be obtained with adherent HEK293T cells…
Citation:
Hein K, Fradin S, Kewes H, Graßl M, Faust N. A novel scalable production platform for gene therapy vectors based on human suspension cell lines. BioProcess J, 2017; 15(4): 8–15. https://doi.org/10.12665/J154.Faust
Posted online February 15, 2017.